LAUSR

1. Pather S, Tejada Berges T, Saidi S, Carter J. Re: Neoadjuvant chemotherapy for advanced ovarian cancer. Who really benefits?. Aust N Z J Obstet Gynaecol 2018; 58: E25-E26. 2. du Bois A, Reuss A, Pujade-Lauraine E et al. Role of surgical outcome as a prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009; 115: 1234–1244. 3. Fagotti A, Ferrandina G, Vizzielli G et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of perioperative outcome. Eur J Cancer 2016; 59: 22–33. 4. Eisenkop SM, Spirtos NM, Montag TW et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992; 47: 203–209. 5. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol 2002; 20: 1248–1259. DOI: 10.1111/ajo.12925